To investigate the effects of rhLK8 or paclitaxel treatment, as a single agent or combination of two drugs, on the expression of VEGF in the tumor tissues, immunohistochemical

staining of VEGF was performed. VEGF expression in SKOV3ip1 tumors was significantly higher than that in HeyA8 tumors, compared to tumors of control groups (Figure W3). Treatment of mice with either paclitaxel or rhLK8 did not significantly alter the expression of VEGF; however, expression of VEGF in tumors of HeyA8 was slightly increased in tumors of mice treated with either paclitaxel or rhLK8 (Figure W3B). Treatment with the combination of paclitaxel MS-275 cost and rhLK8 significantly decreased the expression of VEGF (Figure W3B). Ovarian tumors possess a rich vascular network that is highly dependent on VEGF-mediated angiogenesis [28] and [29].

Therefore, many angiogenesis inhibitors have been evaluated in the preclinical and clinical settings for the treatment of ovarian carcinoma [30]. One of the most extensively studied vascular targeting molecules is bevacizumab (Avastin), which neutralizes Panobinostat manufacturer circulating VEGF and suppresses angiogenesis [31]. Recent phase III clinical trials in first-line ovarian cancers showed that bevacizumab prolonged progression-free survival when administered in combination with chemotherapy [32]. However, the effect of anti-VEGF therapy on overall survival is limited and it is often associated with several clinical toxicities [33] and [34]. Moreover, tumor cells can escape from prolonged anti-VEGF therapy by producing other proangiogenic factors [35]. Therefore, the development of antiangiogenic drugs that are effective independent Carbohydrate of the VEGF status of tumors is critical. Our results clearly showed the efficacy of antiangiogenic therapy with rhLK8 in combination with paclitaxel

on the proliferation of human ovarian carcinoma cells producing high or low levels of VEGF in a xenograft mouse model. We examined two human ovarian cancer cell lines with significantly different VEGF levels and expected to find differences in the biologic activity of the VEGF axis. Tumors derived from SKOV3ip1 cells grew relatively slower, produced higher levels of VEGF, induced the development of ascites, and showed higher MVD, whereas HeyA8 cells formed larger tumors with lower VEGF expression levels that did not produce ascites and showed lower MVD. Treatment with paclitaxel or rhLK8 as a single agent significantly reduced tumor size but not tumor incidence in both models.